Subscribe
shutterstock_580492693_akedesign
akedesign / Shutterstock.com
10 December 2020Big PharmaMuireann Bolger

90% of essential medicines off-patent, study reveals

Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Pfizer off-patent division to merge with Mylan
29 July 2019   Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.
Asia
Takeda sheds off-patent drugs to focus on innovation
17 April 2017   Takeda will sell a number of its off-patent drugs, used for treatment of diabetes, hypertension and peptic ulcers, to Teva Takeda Yakuhin for ¥28.5 billion.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Pfizer off-patent division to merge with Mylan
29 July 2019   Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.
Asia
Takeda sheds off-patent drugs to focus on innovation
17 April 2017   Takeda will sell a number of its off-patent drugs, used for treatment of diabetes, hypertension and peptic ulcers, to Teva Takeda Yakuhin for ¥28.5 billion.

More on this story

Big Pharma
Pfizer off-patent division to merge with Mylan
29 July 2019   Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.
Asia
Takeda sheds off-patent drugs to focus on innovation
17 April 2017   Takeda will sell a number of its off-patent drugs, used for treatment of diabetes, hypertension and peptic ulcers, to Teva Takeda Yakuhin for ¥28.5 billion.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB